210 related articles for article (PubMed ID: 33075130)
1. JAK2V617F myeloproliferative neoplasm eradication by a novel interferon/arsenic therapy involves PML.
Dagher T; Maslah N; Edmond V; Cassinat B; Vainchenker W; Giraudier S; Pasquier F; Verger E; Niwa-Kawakita M; Lallemand-Breitenbach V; Plo I; Kiladjian JJ; Villeval JL; de Thé H
J Exp Med; 2021 Feb; 218(2):. PubMed ID: 33075130
[TBL] [Abstract][Full Text] [Related]
2. Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-α in a murine model of polycythemia vera.
Mullally A; Bruedigam C; Poveromo L; Heidel FH; Purdon A; Vu T; Austin R; Heckl D; Breyfogle LJ; Kuhn CP; Kalaitzidis D; Armstrong SA; Williams DA; Hill GR; Ebert BL; Lane SW
Blood; 2013 May; 121(18):3692-702. PubMed ID: 23487027
[TBL] [Abstract][Full Text] [Related]
3. Arsenic trioxide promoting ETosis in acute promyelocytic leukemia through mTOR-regulated autophagy.
Li T; Ma R; Zhang Y; Mo H; Yang X; Hu S; Wang L; Novakovic VA; Chen H; Kou J; Bi Y; Yu B; Fang S; Wang J; Zhou J; Shi J
Cell Death Dis; 2018 Jan; 9(2):75. PubMed ID: 29362482
[TBL] [Abstract][Full Text] [Related]
4. The arsenic-based cure of acute promyelocytic leukemia promotes cytoplasmic sequestration of PML and PML/RARA through inhibition of PML body recycling.
Lång E; Grudic A; Pankiv S; Bruserud O; Simonsen A; Bjerkvig R; Bjørås M; Bøe SO
Blood; 2012 Jul; 120(4):847-57. PubMed ID: 22692509
[TBL] [Abstract][Full Text] [Related]
5. Biotransformation of arsenic trioxide by AS3MT favors eradication of acute promyelocytic leukemia: revealing the hidden facts.
Maimaitiyiming Y; Zhu HH; Yang C; Naranmandura H
Drug Metab Rev; 2020 Aug; 52(3):425-437. PubMed ID: 32677488
[TBL] [Abstract][Full Text] [Related]
6. JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFNα.
Hasan S; Lacout C; Marty C; Cuingnet M; Solary E; Vainchenker W; Villeval JL
Blood; 2013 Aug; 122(8):1464-77. PubMed ID: 23863895
[TBL] [Abstract][Full Text] [Related]
7. Distinct effects of ruxolitinib and interferon-alpha on murine JAK2V617F myeloproliferative neoplasm hematopoietic stem cell populations.
Austin RJ; Straube J; Bruedigam C; Pali G; Jacquelin S; Vu T; Green J; Gräsel J; Lansink L; Cooper L; Lee SJ; Chen NT; Lee CW; Haque A; Heidel FH; D'Andrea R; Hill GR; Mullally A; Milsom MD; Bywater M; Lane SW
Leukemia; 2020 Apr; 34(4):1075-1089. PubMed ID: 31732720
[TBL] [Abstract][Full Text] [Related]
8. Role of PML SUMOylation in arsenic trioxide-induced fibrosis in HSCs.
Dai J; Hu Y; Niu Q; Song G; Wang H; Li S
Life Sci; 2020 Jun; 251():117607. PubMed ID: 32240679
[TBL] [Abstract][Full Text] [Related]
9. Inferring the dynamics of mutated hematopoietic stem and progenitor cells induced by IFNα in myeloproliferative neoplasms.
Mosca M; Hermange G; Tisserand A; Noble R; Marzac C; Marty C; Le Sueur C; Campario H; Vertenoeil G; El-Khoury M; Catelain C; Rameau P; Gella C; Lenglet J; Casadevall N; Favier R; Solary E; Cassinat B; Kiladjian JJ; Constantinescu SN; Pasquier F; Hochberg ME; Raslova H; Villeval JL; Girodon F; Vainchenker W; Cournède PH; Plo I
Blood; 2021 Dec; 138(22):2231-2243. PubMed ID: 34407546
[TBL] [Abstract][Full Text] [Related]
10. Involvement of PML-I in reformation of PML nuclear bodies in acute promyelocytic leukemia cells by leptomycin B.
Wang C; Su L; Shao YM; Chen WZ; Bu N; Hao R; Ma LY; Hussain L; Lu XY; Wang QQ; Naranmandura H
Toxicol Appl Pharmacol; 2019 Dec; 384():114775. PubMed ID: 31669778
[TBL] [Abstract][Full Text] [Related]
11. Genomic and functional impact of Trp53 inactivation in JAK2V617F myeloproliferative neoplasms.
Gou P; Liu D; Ganesan S; Lauret E; Maslah N; Parietti V; Zhang W; Meignin V; Kiladjian JJ; Cassinat B; Giraudier S
Blood Cancer J; 2024 Jan; 14(1):1. PubMed ID: 38177095
[TBL] [Abstract][Full Text] [Related]
12. Arsenic trioxide preferentially binds to the ring finger protein PML: understanding target selection of the drug.
Kaiming C; Sheng Y; Zheng S; Yuan S; Huang G; Liu Y
Metallomics; 2018 Nov; 10(11):1564-1569. PubMed ID: 30259936
[TBL] [Abstract][Full Text] [Related]
13. Sumoylation of the Tumor Suppressor Promyelocytic Leukemia Protein Regulates Arsenic Trioxide-Induced Collagen Synthesis in Osteoblasts.
Xu WX; Liu SZ; Wu D; Qiao GF; Yan J
Cell Physiol Biochem; 2015; 37(4):1581-91. PubMed ID: 26517826
[TBL] [Abstract][Full Text] [Related]
14. Overview of Transgenic Mouse Models of Myeloproliferative Neoplasms (MPNs).
Dunbar A; Nazir A; Levine R
Curr Protoc Pharmacol; 2017 Jun; 77():14.40.1-14.40.19. PubMed ID: 28640953
[TBL] [Abstract][Full Text] [Related]
15. CUDC-101 overcomes arsenic trioxide resistance via caspase-dependent promyelocytic leukemia-retinoic acid receptor alpha degradation in acute promyelocytic leukemia.
Zhang T; Ma D; Wei D; Lu T; Yu K; Zhang Z; Wang W; Fang Q; Wang J
Anticancer Drugs; 2020 Feb; 31(2):158-168. PubMed ID: 31584454
[TBL] [Abstract][Full Text] [Related]
16. Early and sensitive detection of PML-A216V mutation by droplet digital PCR in ATO-resistant acute promyelocytic leukemia.
Alfonso V; Iaccarino L; Ottone T; Cicconi L; Lavorgna S; Divona M; Cairoli R; Cristiano A; Ciardi C; Travaglini S; Falconi G; Hasan SK; Venditti A; Arcese W; Voso MT; Lo-Coco F
Leukemia; 2019 Jun; 33(6):1527-1530. PubMed ID: 30651632
[No Abstract] [Full Text] [Related]
17. Optimizing IFN Alpha Therapy against Myeloproliferative Neoplasms.
Hermange G; Cournède PH; Plo I
J Pharmacol Exp Ther; 2023 Oct; 387(1):31-43. PubMed ID: 37391225
[TBL] [Abstract][Full Text] [Related]
18. ATR, PML, and CHK2 play a role in arsenic trioxide-induced apoptosis.
Joe Y; Jeong JH; Yang S; Kang H; Motoyama N; Pandolfi PP; Chung JH; Kim MK
J Biol Chem; 2006 Sep; 281(39):28764-71. PubMed ID: 16891316
[TBL] [Abstract][Full Text] [Related]
19. All-trans retinoic acid and arsenic trioxide fail to derepress the monocytic differentiation driver Irf8 in acute promyelocytic leukemia cells.
Liu X; Chen J; Yu S; Yan L; Guo H; Dai J; Zhang W; Zhu J
Cell Death Dis; 2017 May; 8(5):e2782. PubMed ID: 28492552
[TBL] [Abstract][Full Text] [Related]
20. Activation of PPARγ intensified the effects of arsenic trioxide in acute promyelocytic leukemia through the suppression of PI3K/Akt pathway: Proposing a novel anticancer effect for pioglitazone.
Esmaeili S; Safaroghli-Azar A; Pourbagheri-Sigaroodi A; Salari S; Gharehbaghian A; Hamidpour M; Bashash D
Int J Biochem Cell Biol; 2020 May; 122():105739. PubMed ID: 32169580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
